



Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China

Fei Yu ^a, Lanying Du ^b, David M. Ojcius ^c, Chungen Pan ^{d, *}, Shibo Jiang ^{b, e, **}

^a The College of Life and Sciences, Hebei Agricultural University, Bao Ding, China

^b Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA

^c Department of Biomedical Sciences, University of the Pacific, School of Dentistry, San Francisco, USA

^d Guangdong Haid Institute of Animal Husbandry & Veterinary, Haid Research Institute, Guangdong Haid Group Co., Ltd, Guangzhou, China

^e Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, China

ARTICLE INFO

Article history:

Received 24 January 2020

Accepted 24 January 2020

Available online 1 February 2020

Keywords:

2019-nCoV

Diagnosis

Preventive

Therapeutic

ABSTRACT

On 10 January 2020, a new coronavirus causing a pneumonia outbreak in Wuhan City in central China was denoted as 2019-nCoV by the World Health Organization (WHO). As of 24 January 2020, there were 887 confirmed cases of 2019-nCoV infection, including 26 deaths, reported in China and other countries. Therefore, combating this new virus and stopping the epidemic is a matter of urgency. Here, we focus on advances in research and development of fast diagnosis methods, as well as potential prophylactics and therapeutics to prevent or treat 2019-nCoV infection.

© 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Coronaviruses (CoVs), which are enveloped, positive-sense, single-stranded RNA viruses of zoonotic origin and belong to the family Coronaviridae in the order Nidovirales, are divided into four genera: alpha, beta, delta and gamma coronavirus. The emerging CoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), both belonging to beta coronavirus, have caused recent pandemics of respiratory infectious diseases with high mortality.

At the end of December 2019, the Wuhan Municipal Health Commission reported the outbreak of viral pneumonia caused by an unknown pathogen in Wuhan, China [1]. Subsequently, the unknown pathogen was identified as a novel coronavirus denoted as 2019-nCoV by the World Health Organization (WHO) on 10 January 2020 [1]. On 12 and 13 January 2020, the full genomic sequence of 2019-nCoV, denoted WIV04 strain (GISAID accession

no. EPI_ISL_402124), was released, with about 82% homology to that of SARS-CoV Tor2 (GenBank accession no. AY274119) and bat SARS-like coronavirus WIV1 (bat SL-CoV-WIV1, GenBank accession no. KF367457.1).

By 24 January, this new emerging virus had caused 887 confirmed cases, including 26 deaths, in the original epidemic area, Wuhan, and other cities in China and in foreign countries. More seriously, 15 healthcare workers were infected with 2019-nCoV after close contact with one infected patient, suggesting human-to-human transmission of 2019-nCoV.

Improved molecular technologies made it possible to rapidly identify this novel coronavirus. In this review, we summarize advances made in technologies for rapid diagnosis and identification of respiratory infections caused by coronavirus, as well as strategies for research and development of vaccines, prophylactics and therapeutics to combat 2019-nCoV and other emerging coronaviruses now or in the future.

1. Rapid identification of an emerging coronavirus

Identification of pathogens mainly includes virus isolation and viral nucleic acid detection. According to the traditional Koch's postulates, virus isolation is the "gold standard" for virus diagnosis

* Corresponding author. Haid Research Institute, Guangdong Haid Group Co., Ltd, 5 Eighth Street, Fu Ping Road, Guangzhou 511400, China.

** Corresponding author. School of Basic Medical Sciences, Fudan University, 131 Dong An Road, Fuxing Building, Xuhui District, Shanghai 200032, China.

E-mail addresses: chungenp@163.com (C. Pan), shibojiang@fudan.edu.cn (S. Jiang).

in the laboratory. First, viral culture is a prerequisite for diagnosing viral infections. A variety of specimens (such as swabs, nasal swabs, nasopharynx or trachea extracts, sputum or lung tissue, blood and feces) should be retained for testing in a timely manner, which gives a higher rate of positive detection of lower respiratory tract specimens. Then, immunological methods – including immunofluorescence assay, protein microarray, direct fluorescent antibody assay, MAb-based rapid NP (nucleocapsid protein) detection, semiconductor quantum dots, and the microneutralization test – which measure binding between the antigen from the whole virus or protein of the coronavirus and corresponding antibody, are easy to operate rapidly but have a lower sensitivity and specificity [3,4]. In addition, other immunological methods, including microneutralization ppNT assay (pseudo-particle neutralization) are highly sensitive and specific by using the gene coding for the coronavirus spike protein [5,6]. In the case of 2019-nCoV, viral research institutions can conduct preliminary identification of the virus through the classical Koch's Postulates or observing its morphology through an electron microscopy [7]. Serology could also be used to identify the virus when 2019-nCoV-associated antigens and monoclonal antibodies are developed in the future [7–9]. All the examples above are traditional virus detection methods.

Viral nucleic acids can also be used for early diagnosis. The following are some of the new coronavirus detection methods. Polymerase chain reaction (PCR) is a molecular biological diagnosis technology based on the sequence of nucleic acids. The full gene sequence of 2019-nCoV has now been obtained [10], so patients who are suspected of being infected with 2019-nCoV [8] can be diagnosed by pan-coronavirus PCR for virus identification [11]. Reverse transcription polymerase chain reaction (RT-PCR) is a technology combining RNA reverse transcription (RT) with polymerase chain amplification (PCR) of cDNA. A duplex RT-PCR assay can be used to detect SARS-CoV and MERS-CoV using pUC57SARS-ps2 and pGEM-MERSS2 as templates, respectively [12]. Also, samples collected from the upper respiratory tract (oropharyngeal and nasopharyngeal) and lower respiratory tract (endotracheal aspirate, expectorated sputum, or bronchoalveolar lavage) of suspected 2019-nCoV patients can be diagnosed by RT-PCR [8]. Reverse transcription-insulated isothermal polymerase chain reaction (RT-iPCR), quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR), Real-time RT-PCR (rtRT-PCR), and one-step rtRT-PCR were all further optimized [13–16]. These optimized RT-PCR methods were used to detect the MERS-CoV envelope gene (upE) and the open reading frame 1a (ORF1a) or open reading frame 1b (ORF1b) genes separately. However, rtRT-PCR was used to identify 2019-nCoV through preliminary and validation detection of its E gene, RNA-dependent RNA polymerase (RdRp) gene, and N gene [17].

There are other molecular-based detection techniques in addition to RT-PCR and similar optimized detection techniques. For example, reverse transcription loop-mediated isothermal amplification (RT-LAMP) is an RNA amplification technique that detects the N gene of MERS-CoV and the ORF1a gene [18]. One-pot reverse transcription loop-mediated isothermal amplification (one-pot RT-LAMP) is the optimized RT-LAMP [19], while RT-LAMP-VF is the deformation of RT-LAMP [20], which is the combination of reverse transcription loop-mediated isothermal amplification and vertical flow visualization strips. Both are used to detect the N gene of MERS-CoV, making detection easier, faster, more efficient and highly specific. Besides these three methods, reverse transcription recombinase polymerase amplification assay (RT-PRA) is also used to identify MERS-CoV [21].

Finally, the following multiplex tests can detect both coronaviruses and other viruses. MCoV-MS (multiplexed CoV mass spectrometry) uses an array matrix-assisted laser desorption/ionization

time-of-flight mass spectrometry (MALDI-TOF MS) system to accurately identify known human coronaviruses (hCoVs) and to provide phylogenetic evidence for emerging unknown hCoVs [22]. Another new test method, arch-shaped multiple-target sensor, is used to amplify the target for rapid identification of pathogens in clinical samples [23]. The method can detect hCoVs, and Zika and Ebola viruses. The last one, the paper-based colorimetric assay, uses Pyrrolidinyl Peptide Nucleic Acid-induced silver nanoparticles (AgNPs) aggregation of pathogen DNA testing [24]. The color change of AgNPs can distinguish between MERS-CoV, *Mycobacterium tuberculosis* (MTB), and human papillomavirus (HPV).

2. Research and development of vaccines

The cellular receptors of SARS-CoV and MERS-CoV have been identified [25,26], and the virion spike (S) glycoprotein, was also well studied. S glycoprotein includes two subunits [27], S1 and S2, resulting from cleavage of the one precursor into two parts. S1 determines the virus host range and cellular tropism with the key functional domain – receptor binding domain (RBD), while S2 contains two tandem domains, heptad repeats 1 (HR1) and heptad repeats 2 (HR2), to mediate virus-cell membrane fusion. It is believed that the fusion process is similar to that of HIV-1 [28]; for example, when S1 binds to the receptor on the cell membrane, the fusion peptide at the N terminus of S2 inserts into the cell membrane, then three HR1s attach to each other in parallel as a trimer, followed by binding of three HR2s separately onto the outside of the trimer to form a 6-helix bundle, thus bringing virus and cell membranes close to each other to trigger fusion.

As the major vaccine target, the S protein has been evaluated in different types of vaccines against infection by CoVs [29]. Apart from the inactive whole virus particle [30], live attenuated virus with gene deletion [31], four more vaccines which mainly contain S protein were studied. These include a virus-like particle which incorporated S protein into hepatitis virus or influenza virus protein [32,33]; virus vectors, such as modified vaccinia virus Ankara (MVA) or Adenovirus carrying S protein [34,35]; S protein subunit vaccine, like RBD-based protein [29,36]; and DNA vaccine which encodes the full length or part of the S protein gene [37,38]. Most of them have been tested in mouse models and showed the ability to elicit neutralizing antibodies. The first SARS-CoV DNA vaccine was tested in humans only 19 months after the virus sequence was published [38], while the DNA vaccine GLS-5300, the first MERS-CoV vaccine, went to clinical trials in 2016 [39]. In addition to these conventional vaccines, Liu et al. analyzed the T cell epitopes of SARS-CoV and MERS-CoV, revealed the potential cross-reactivity of the coronaviruses, and assessed the possibility of developing universal vaccines against coronavirus infections [40].

Most CoVs share a similar viral structure, similar infection pathway, and a similar structure of the S proteins [41], suggesting that similar research strategies should also be applicable for the 2019-nCoV. For example, the study of MERS-CoV vaccines was accelerated by virtue of strategies that had been established for SARS-CoV [42]. It has been reported that the 2019-nCoV is also genetically close to SARS-CoV [43,44]. Therefore, to predict whether vaccines developed for SARS-CoV will also be effective against 2019-nCoV infection, the full length S protein sequences from the 2019-nCoV, a SARS-CoV, and two genetically similar bat CoV strains were selected for alignment (Fig. 1). The results indicated more than 50% homology of the viruses. However, the most variable residues are located in S1, a critical vaccine target, implying that neutralizing antibodies that were so effective against SARS-CoV infection may fail to recognize the 2019-nCoV, and that multiple amino acid differences at the receptor binding motif may modify virus tropism, a possible reason for cross-species transmission.

2019-nCoV	MFLLTTRKTM	FVFLVLLPLV	S----SQCVN	LTTRTQLPPA	YTNSFTRGVY	YDPKVFRRSSV	LHSTQDLFLP	FFSNVTWFHA
bat-SL-CoVZC45	-----ML	.FLFLQFA.	N-----	.G.P.N.N	...SQ....	..TIY..DT	.VLS.GY...	.Y...S.YYS
bat-SL-CoVZXC21	-----ML	.FLFLQFA.	N-----D-	.G.P.N.N	...SQ....	..TIY..DT	.VLS.GY...	.Y...S.YYS
SARS-CoV	-----	.I.LF.T.T	.GSDLDR.TT	FDDVQAPNYT	QHT.SM....	..EI...DT	.YL.....	.Y...G..T
2019-nCoV	IHSVGTNGTK	RFDNPVLPFN	DGVYFASTEK	SNIIRGWIFG	TTLDSKTQSL	LIVNNATNVV	IKVCFEQFCN	DPFLGVVYHK
bat-SL-CoVZC45	LTTN-NAA.	.T...I.D.K	.I...A..HNTS...I	...N.D..Y	.Y.SG...-
bat-SL-CoVZXC21	LTTN-NAA.	.T...I.D.K	.I...A..HNTS...I	...N.D..Y	.Y.SG...-
SARS-CoV	.NHT-----	-.I...I..K	.I...A...	..VV...V.	S.MNN.S..V	I.I.S....	.RA.N.EL.D	N..FA.SKP-
2019-nCoV	NNKSWMESEF	RVYSSANNCT	FEYVSQPFML	DLEGKQGNFK	NLREFVFKNI	DGYFKIYSKH	TPINLVRDLP	QGFSALEPLV
bat-SL-CoVZC45	..T.SIR..	A...YA...	...KS.ML	NIS.NG.L.N	T.....R.V	..H.....F	..V..N.G..	T.L.V.Q...
bat-SL-CoVZXC21	..T.SIR..	A...FYA...	...KS.ML	NIS.NG.L.N	T.....R.V	..H.....F	..V..N.G..	T.L.V.Q...
SARS-CoV	---MGTQTH	MIFDN.F...	..I.DA.SL	.VSE.S...	H.....K	..FLV.V.KGY	Q..DV....	S..NT.K.IF
2019-nCoV	DLPIGINITR	FQTLALHRS	YLTPGDSGSSG	WTAGAAAYV	GYLQPRTFLL	KYNENGTITD	AVDCALDPLS	ETKCTLKS
bat-SL-CoVZC45	E..VS...K	R...TI..G	DPM---NN.	..FS..F.	...K...M.L.
bat-SL-CoVZXC21	E..VS...K	R...TI..G	DPM---NN.	..FS..F.	...K...M.L.
SARS-CoV	K..L....N	.RAI.TAFLP	AQDT-----	.GTS...F.	...K.T..M.	..D.....	...SQN..A	.L..SV...E
2019-nCoV	VEKGIYQTSN	FRVQPTESIV	RFPNITNLCP	FGEVFNATRF	ASVYAWNRKR	ISNCVADYSV	LYNSASFSTF	KCYGVSPTKL
bat-SL-CoVZC45	.Q.....	...Q.V.	...V..	.HK.....	P...E.TK	.D.I...T	F...T....	...S.
bat-SL-CoVZXC21	.Q.....	...Q.V.	...V..	.HK.....	P...E.TK	.D.I...T	F...T....	...S.
SARS-CoV	ID.....	..V.SRDV.K.	P...E..	..D.....	...TF	...A.
2019-nCoV	NDLCTFNVA	DSFVIRGDEV	RQIAPGQTGK	IADYNYKLDP	DFTGCVIAWN	SNNLDSKVGG	NYNYLYRFR	KSNLKPFRD
bat-SL-CoVZC45	I...S...	.T.L.FS..	.V...V	TAKQ.--.-	--.F.SH.	STK.....
bat-SL-CoVZXC21	I...S...	.T.L.FS..	.V...V	TAKQ.--.-	--.F.SH.	STK.....
SARS-CoV	...S...	..VK..D.	..V...V	M..L.	TR.I.ATST	..K..YL.	HGK.R....
2019-nCoV	ISTEIQAGS	TPCNGVEGFN	CYFPLQSYGF	QPTNGVGYQP	YRVVLSFEL	LHAPATVCGP	KKSTNLVKNK	CVNFNENGLT
bat-SL-CoVZC45	L.SDE----	---.R---	---T.ST.D	N.NVPLE..A	T.....	.N.....	.L.Q...Q	...K
bat-SL-CoVZXC21	L.SDE----	---.R---	---T.ST.D	N.NVPLE..A	T.....	.N.....	.L.Q...Q	...K
SARS-CoV	..NVFSPDG	K..TPPALN-	.W..ND..	YT.T.I...Y.	.N.....	.L..D.I..Q
2019-nCoV	GTGVLTESNK	KFLPFQQFGR	DIADTTDAVR	DPQTLLEILD	TPCSFGGVS	ITPGTNTSNQ	VAVLYQDVNC	TEVPVAIHAD
bat-SL-CoVZC45D.S	R.QS...K	.AS.FI.S.LED.	TT...
bat-SL-CoVZXC21D.S	R.QS...K	.AS.FI.S.SED.	TT...
SARS-CoVP.S	R.Q...K	.VS.F.S.	..K.S...	S.....A.SED.	ST...
2019-nCoV	QLTPTWRVYS	TGSNVFQTRA	GCLIGAEHVN	NSYECDIPIG	AGICASYQTQ	TNSPRRARSV	ASQSIIAYTM	SLGAENSVA
bat-SL-CoVZC45	...A..I.A	.T...Q.	A.....	...H.A	S---IL.T	SQKA.V...	...I.
bat-SL-CoVZXC21	...A..I.A	I.TS...Q.	A.....	...H.A	S---IL.T	GQKA.V...	...I.
SARS-CoV	...A..I.	.N...Q.D	T.....	...H.V	S---LL.T	SQK.V...	...DS.I.
2019-nCoV	SNNIAIPTN	FTISVTTEIL	PVSMTKTSVD	CTMYICGDST	ECSNLLLYG	SFCTQLNRAL	TGIAVEQDKN	TQEVFAQVKQ
bat-SL-CoVZC45	A.....	.S...VM	..A...I	S...I...
bat-SL-CoVZXC21	A.....	.S...VM	..A...I	S...I...
SARS-CoV	..T.....	.S..I..VM	..A...	.N.....	..A.....	S...A..R.	R.....
2019-nCoV	IYKTPPIKDF	GGFNFSQILP	DPSKPSKRSF	IEDLLFNKVT	LADAGFIKQY	GDCLGDIAR	DLICAQKENG	LTVLPLPLTD
bat-SL-CoVZC45G.S.
bat-SL-CoVZXC21S.
SARS-CoV	M...TL...L.ST...M.	..E...N.
2019-nCoV	EMIAQYTSAL	LAGTITSGWT	FGAGAALQIP	FAMQMAYRFN	GIGVTQNVLY	ENQKLIANQF	NSAIGKIQDS	LSSTASALGK
bat-SL-CoVZC45	...A..A.	IS..A.A.E..T.
bat-SL-CoVZXC21	...A..A.	IS..A.A.E..T.
SARS-CoV	D...A..A.	VS..A.A.Q....	.K..SQ..E.	TT.ST...
2019-nCoV	LQDVVNQNAQ	ALNLTQVQLS	SNFGAIVSVL	NDILSRLLDKV	EAEVQIDRLI	TGRLQSLQTY	VTQQLIRAAE	IRASANLAAT
bat-SL-CoVZC45
bat-SL-CoVZXC21
SARS-CoV
2019-nCoV	KMSECVLQGS	KRVDFCGKGY	HMSFPQSAP	HGVVFLHVTY	VPAQEKNTT	APAICHGDKA	HFPREGVFS	NGTHWFVTQR
bat-SL-CoVZC45	I.S.....E.
bat-SL-CoVZXC21	I.S.....E.
SARS-CoVA.S.R....E.	Y.....F	..S..I..
2019-nCoV	NFYEPQIITT	DNTFVSGNCD	VVIGIVNNTV	YDPLQPELDS	FKEELDKYFK	NHTSPD	DVDLG	DISGINASVV
bat-SL-CoVZC45	...K...I...I..	NIQKEIDRLN
bat-SL-CoVZXC21	...K...I...I..	NIQKEIDRLN
SARS-CoV	..FS...I...I..	NIQKEIDRLN
2019-nCoV	EVAKNLNESL	IDLQELGKYE	QYIKWBYWYI	LGFIAGLIAI	VMVTIMLCCM	TSCCSCLKGC	CSCGSCCKFD	EDDSEPVKLG
bat-SL-CoVZC45	..R.....V.L...
bat-SL-CoVZXC21	..R.....	H...V.L...
SARS-CoVV.L...A
2019-nCoV	VKLHYT	100%						
bat-SL-CoVZC45	61%						
bat-SL-CoVZXC21	62%						
SARS-CoV	54%						

Fig. 1. Comparison of S protein sequences of coronaviruses. Multiple alignment of full amino acid sequences of S protein from 2019-nCoV (GISAID accession no. EPI_ISL_402124), SARS-CoV (GenBank accession no. AY278489), bat-SL-CoVZC45 (GenBank accession no. MG772933.1), and bat-SL-CoVZXC21 (GenBank accession no. MG772934.1) was performed and displayed with clustalx1.83 and MEGA4 respectively. "-" represents the unconfirmed amino acid residues, "." represents the identical amino acid residues. The functional domains were labeled based on the research on SARS-CoV [41]; light blue box was for RBD region; dark blue box for receptor binding motif (RBM); light purple box for HR1; and dark purple box for HR2, respectively. Double underlined regions in HR1 and HR2 are fusion cores, which are critical regions responsible for the formation of stable six-helical bundles between HR1 and HR2.

However, several bottlenecks typically delay the approval of vaccines to prevent CoVs infection. First, a lack of proper animal models for evaluating vaccine efficacy. Second, there are limitations from the S protein itself, such as mutations in the neutralization antibody epitopes in S protein that can cause virus escape [45], or non-neutralization antibody epitopes in vaccines that may elicit antibody-mediated disease enhancement (ADE) [46]. Third, DNA vaccines may recombine with other viruses. Fourth, pre-existing immunity may eliminate the vaccine by removing the general human virus vectors [47]. Finally, there is the problem of return on investment which may be slow and, hence, inhibit investments and slow down the clinical study.

Jiang and colleagues have demonstrated that RBD in the SARS-CoV S protein is the major target of neutralizing antibodies in SARS patients and is able to induce highly potent neutralizing antibody responses and long-term protective immunity in animal models. It contains 6 different conformational neutralizing epitopes, to which a series of mouse monoclonal antibodies (mAbs) with different neutralizing activity were generated. Interestingly, these mAbs exhibited cross-neutralizing activities against divergent SARS-CoV strains isolated from SARS patients at different stages of SARS epidemics in 2002–2004 and those from palm civets [48–52]. This group has also shown that these SARS-CoV-RBD-specific neutralizing mAbs can cross-neutralize bat SL-CoVs, such as bat SL-CoV-W1V1 [53], indicating that these antibodies may also cross-neutralize 2019-nCoV. Most importantly, RBD-based vaccine could induce neutralizing antibody responses and protection against SARS-CoV infection in the immunized animals, while it did not elicit ADE or other harmful immune responses, unlike the virus-inactivated vaccines or full-length S protein-based vaccines as discussed above. Therefore, this RBD-based SARS vaccine is expected to be safer and more effective than the vaccines targeting other sites in S protein. Jiang and Du's groups have collaborated with Hotez's group at Baylor College of Medicine in Houston and Tseng's group at the University of Texas Medical Branch at Galveston, Texas, USA in development of an effective and safe vaccine at the late stage of preclinical study [54]. The antibodies induced by this vaccine candidate are expected to cross-neutralize 2019-nCoV infection. If it is confirmed, this vaccine candidate has the great potential to be further developed promptly in clinical trials in both China and the United State through the continuous collaborations among the four groups of Drs. Hotez, Tseng, Du, and Jiang [55].

3. Research and development of therapeutics and prophylactics

At the present, no specific antiviral therapy has been approved for treatment of infection by human CoVs. As development of vaccines and compounds for prevention and treatment of infection have been brought to priority status by WHO and governments [56], numerous drug studies have been done or are moving forward. Some of them focus on the CoV fusion/entry process either by inhibition of S1 mediated virus attachment or by blocking of S2 mediated virus-cell membrane fusion, and some of them interfere with viral replication [57].

3.1. CoV fusion/entry inhibitors

Based on the previous experience in developing the HIV-1 fusion inhibitor SJ-2176 [58], Jiang et al. discovered the first anti-SARS-CoV peptide (SC-1) from the HR2 domain of SARS-CoV S protein S2 subunit. SC-1 could bind onto the HR1 domain to form a six-helical bundle (6-HB), blocking S protein-mediated membrane fusion and inhibiting SARS-CoV infection [59]. When MERS-CoV was circulating in human populations in 2012, following similar

mechanistic design, Jiang's research group developed another peptide, designated HR2P, which was derived from the virus HR2 region as well and effectively inhibited MERS-CoV infection [60]. The further modified version of HR2P, HR2P-M2, presented even better anti-MERS-CoV activity and pharmaceutical properties.

Development of broad-spectrum pan-CoV fusion inhibitors would be an ideal way to cope with epidemics or pandemics caused by emerging HCoVs. The conservative amino acid sequence of the HR1 region across different CoVs has the potential to be a target domain for development of an inhibitor. Continuing to work on the HR1 and HR2 domains, Jiang's group discovered that the peptide OC43-HR2P, derived from the HR2 domain of HCoV-OC43, broadly inhibited fusion by multiple HCoVs. By optimization of this peptide, a pan-CoV fusion inhibitor, EK1, was generated. It could form a stable six-helix bundle (6-HB) structure with HR1s and showed significantly improved fusion-inhibitory activity and pharmaceutical properties [61]. The alignment of S protein in Fig. 1 exhibited 100% identity at the HR2 domains between the 2019-nCoV and SARS-CoV; however, they found 7 amino acid changes in the fusion core of the HR1, located in the EK1 binding motif. Fortunately, the substitutions were conservative replacements which would not dramatically disrupt the interactions between EK1 and HR1, meaning that EK1 would still have the potential to be an effective inhibitor for 2019-nCoV infection.

3.2. CoV S-RBD-specific neutralizing antibodies

So far, most neutralizing antibodies recognize the RBD in the S protein S2 of CoVs. Compared with the high mutation rate in the S1 protein, S2 is much more conservative, thereby decreasing the off-target risk caused by amino acid replacement [62], and also bypassing the special epitopes that may cause ADE [63]. This means that the cocktail of monoclonal antibodies binding to different epitopes of RBD would be more desirable for therapeutic purposes [64]. For treatment, the monoclonal antibodies are from a human source or are humanized antibodies, isolated or generated with various approaches. For example, wild-type mice were immunized with soluble recombinant RBD containing the S protein. Then mouse antibodies were humanized and isolated, or transgenic mice were directly immunized, to express human versions of the antibodies [50,65,66]. However, direct cloning of single B cells from human survivors, used in combination with the phage-display antibody library, could provide authentic human antibodies. Until now, it should be noted that many neutralizing antibodies have been successfully discovered for treatment of SARS-CoV [67] and MERS-CoV infection [45,68,69]. These antibodies have all been described favorably in the literature [29,70,71]. A similar approach is known as single chain fragment variable (scFv) library screening, whereby the use of RBD as a bait protein allows some neutralizing antibodies to be screened out from non-immune humans [72,73].

Antibodies effective at inhibiting SARS-CoV infection should also have the potential for treatment of 2019-nCoV as well, as long as the binding motif in RBD shares the same sequences. The new neutralizing monoclonal antibodies would also be isolated from the patients using the established techniques.

3.3. CoV replication inhibitors

Similar to developing vaccines, drugs effective against other RNA viruses were also repurposed for CoVs. Two major types of drugs being nucleoside analogues and immunomodulators. So far, the most common therapies tried in patients with CoVs are ribavirin, lopinavir/ritonavir, IFN, or their combinations [74]. Despite the antiviral activity observed with *in vitro* studies, the clinical effect was not consistent [75], in that ribavirin does not prolong the

survival of SARS-CoV patients [74,76], while lopinavir/ritonavir plus ribavirin seemed to improve clinical outcomes for SARS patients [77], but the improvement was not confirmed in MERS-CoV patients. IFNs showed effective at inducing antiviral activity against both SARS-CoV and MERS-CoV, but without significant improvement in the outcomes for the patients [78,79]. In addition to the drug regimens used in patients, numerous drugs developed for the treatment of infection with CoVs were thoroughly discussed in the literature [57].

However, replication of an RNA virus usually generates progeny viruses with a highly diverse genome. Recombination also easily takes place between viral genomes [80], and these gene level changes may result in drug resistance if the mutations affect the drug target domain. Development of drugs is also hampered by various evaluation methods and animal models used for testing drug activity among different labs worldwide, which could postpone selection of the best drug for clinical trials.

4. Conclusion and prospects

Taken together, 2019-nCoV is a new coronavirus, and like SARS-CoV and MERS-CoV, it belongs to *Betacoronavirus*. Both SARS-CoV and MERS-CoV were able to spread around the globe and posed a major challenge to clinical management and a great threat to public health. Similarly to SARS-CoV and MERS-CoV, based on the monitoring and scientific forecast, 2019-nCoV may cause a worldwide threat to public health. Over the years, research on CoVs has resulted in multiple strategies for diagnosis, prevention and treatment of CoV infection. This brief review has demonstrated that such an achievement could very well apply to 2019-nCoV, or indeed, any newly emergent CoV in the future. At present, many companies engaged in the development of biologicals have marketed nucleic acid detection kits for 2019-nCoV, such as the new coronavirus nucleic acid detection kit (double fluorescence PCR method) from Shuoshi Biotechnology. Currently, however, no diagnostic test kit is available for the detection of antibodies to 2019-nCoV.

Declaration of Competing Interest

The authors declare that they have no conflicts of interest.

Acknowledgements

We thank Dr. Zengli Shi for providing us permission for analysis of the spike protein sequence of 2019-nCoV (GISAID accession no. EPI_ISL_402124) in this study.

References

- [1] WHO. <https://www.who.int/emergencies/en/>.
- [2] Chan KH, Chan JF, Tse H, Chen H, Lau CC, Cai JP, et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. *J Infect* 2013;67:130–40.
- [3] Aburizaiza AS, Mattes FM, Azhar EI, Hassan AM, Memish ZA, Muth D, et al. Investigation of anti-middle East respiratory syndrome antibodies in blood donors and slaughterhouse workers in Jeddah and Makkah, Saudi Arabia, fall 2012. *J Infect Dis* 2014;209:243–6.
- [4] Reusken C, Mou H, Godeke GJ, van der Hoek L, Meyer B, Muller MA, et al. Specific serology for emerging human coronaviruses by protein microarray. *Euro Surveill* 2013;18:20441.
- [5] Zhao G, Du L, Ma C, Li Y, Li L, Poon VK, et al. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. *Virology* 2013;10:266.
- [6] Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. *J Med Virol* 2020;92[:???:??].
- [7] WHO. https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf?sfvrsn=bc7da517_2.
- [8] WHO. https://www.who.int/docs/default-source/coronaviruse/20200114-int-erim-laboratory-guidance-version.pdf?sfvrsn=6967c39b_4&download=true.
- [9] <https://www.gisaid.org/>.
- [10] <http://virological.org/t/initial-assessment-of-the-ability-of-published-coronavirus-primers-sets-to-detect-the-wuhan-coronavirus/321>.
- [11] Noh JY, Yoon SW, Kim DJ, Lee MS, Kim JH, Na W, et al. Simultaneous detection of severe acute respiratory syndrome, Middle East respiratory syndrome, and related bat coronaviruses by real-time reverse transcription PCR. *Arch Virol* 2017;162:1617–23.
- [12] Go YY, Kim YS, Cheon S, Nam S, Ku KB, Kim M, et al. Evaluation and clinical validation of two field-deployable reverse transcription-insulated isothermal PCR assays for the detection of the Middle East respiratory syndrome-coronavirus. *J Mol Diagn* 2017;19:817–27.
- [13] Lu X, Whitaker B, Sakthivel SK, Kamili S, Rose LE, Lowe L, et al. Real-time reverse transcription-PCR assay panel for Middle East respiratory syndrome coronavirus. *J Clin Microbiol* 2014;52:67–75.
- [14] Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. *Euro Surveill* 2012;17:20285.
- [15] Hashemzadeh MS, Rasouli R, Zahraei B, Izadi M, Tat M, Saadat SH, et al. Development of dual TaqMan based one-step rRT-PCR assay panel for rapid and accurate diagnostic test of MERS-CoV: a novel human coronavirus, ahead of Hajj pilgrimage. *Iran Red Crescent Med J* 2016;18:e23874.
- [16] WHO. https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-ssho-v1991527e5122341d99287a1b17c111902.pdf?sfvrsn=d381fc88_2.
- [17] Shirato K, Yano T, Senba S, Akachi S, Kobayashi T, Nishinaka T, et al. Detection of Middle East respiratory syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP). *Virology* 2014;11:139.
- [18] Lee SH, Baek YH, Kim YH, Choi YK, Song MS, Ahn JY. One-pot reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) for detecting MERS-CoV. *Front Microbiol* 2016;7:2166.
- [19] Huang P, Wang H, Cao Z, Jin H, Chi H, Zhao J, et al. A rapid and specific assay for the detection of MERS-CoV. *Front Microbiol* 2018;9:1101.
- [20] Abd El Wahed A, Patel P, Heidenreich D, Hufert FT, Weidmann M. Reverse transcription recombinase polymerase amplification assay for the detection of middle East respiratory syndrome coronavirus. *PLoS Curr* 2013;5.
- [21] Xiu L, Zhang C, Wu Z, Peng J. Establishment and application of a universal coronavirus screening method using MALDI-TOF mass spectrometry. *Front Microbiol* 2017;8:1510.
- [22] Koo B, Hong KH, Jin CE, Kim JY, Kim SH, Shin Y. Arch-shaped multiple-target sensing for rapid diagnosis and identification of emerging infectious pathogens. *Biosens Bioelectron* 2018;119:79–85.
- [23] Teengam P, Siangproh W, Tuantranont A, Vilaivan T, Chailapakul O, Henry CS. Multiplex paper-based colorimetric DNA sensor using Pyrrolidinyl peptide nucleic acid-induced AgNPs aggregation for detecting MERS-CoV, MTB, and HPV Oligonucleotides. *Anal Chem* 2017;89(10):5428–5435.
- [24] Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. *Nature* 2013;495:251–4.
- [25] Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* 2003;426:450–4.
- [26] Zhang N, Jiang S, Du L. Current advancements and potential strategies in the development of MERS-CoV vaccines. *Expert Rev Vaccines* 2014;13:761–74.
- [27] Wang X, Xiong W, Ma X, Wei M, Chen Y, Lu L, et al. The conserved residue Arg46 in the N-terminal heptad repeat domain of HIV-1 gp41 is critical for viral fusion and entry. *PLoS One* 2012;7:e44874.
- [28] Zhou Y, Yang Y, Huang J, Jiang S, Du L. Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain. *Viruses* 2019;11:E60.
- [29] Agrawal AS, Tao X, Algaissi A, Garron T, Narayanan K, Peng BH, et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. *Hum Vaccines Immunother* 2016;12:2351–6.
- [30] Fett C, DeDiego ML, Regla-Nava JA, Enjuanes L, Perlman S. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. *J Virol* 2013;87:6551–9.
- [31] Lokugamage KG, Yoshikawa-Iwata N, Ito N, Watts DM, Wyde PR, Wang N, et al. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. *Vaccine* 2008;26:797–808.
- [32] Liu YV, Massare MJ, Barnard DL, Kort T, Nathan M, Wang L, et al. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. *Vaccine* 2011;29:6606–13.
- [33] Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H, et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. *J Virol* 2015;89:8651–6.
- [34] Munster VJ, Wells D. Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. *npj Vaccines* 2017;2:28.

- [36] Du L, Ma C, Jiang S. Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC. *J Infect* 2013;67:348–50.
- [37] Chi H, Zheng X, Wang X, Wang C, Wang H, Gai W, et al. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. *Vaccine* 2017;35:2069–75.
- [38] Martin JE, Louder MK, Holman LA, Gordon JJ, Enama ME, Larkin BD, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. *Vaccine* 2008;26:6338–43.
- [39] Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. *Lancet Infect Dis* 2019;19:1013–22.
- [40] Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, et al. T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. *Antivir Res* 2017;137:82–92.
- [41] Yuan Y, Cao D, Zhang Y, Ma J, Qi J, Wang Q, et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. *Nat Commun* 2017;8:15092.
- [42] Du L, Jiang S. Middle East respiratory syndrome: current status and future prospects for vaccine development. *Expert Opin Biol Ther* 2015;15:1647–51.
- [43] Chen JFW, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from patients with acute respiratory disease in Wuhan, Hubei, China. *Emerg Microb Infect* 2020;9 [???-???].
- [44] Jiang S, Du L, Shi Z. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. *Emerg Microb Infect* 2020;9 [???-???].
- [45] Wang L, Shi W, Chappell JD, Joyce MG, Zhang Y, Kanekiyo M, et al. Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the Middle East respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape. *J Virol* 2018;92:e02002–17.
- [46] Olsen CW. A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination. *Vet Microbiol* 1993;36:1–37.
- [47] Long BR, Sandza K, Holcomb J, Crockett L, Hayes GM, Arens J, et al. The impact of pre-existing immunity on the non-clinical pharmacodynamics of AAV5-based gene therapy. *Mol Ther Methods Clin Dev* 2019;13:440–52.
- [48] He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. *Biochem Biophys Res Commun* 2004;324:773–81.
- [49] He Y, Zhou Y, Siddiqui P, Jiang S. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. *Biochem Biophys Res Commun* 2004;325:445–52.
- [50] He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. *J Immunol* 2005;174:4908–15.
- [51] He Y, Zhu Q, Liu S, Zhou Y, Yang B, Li J, et al. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. *Virology* 2005;334:74–82.
- [52] He Y, Li J, Li W, Lustigman S, Farzan M, Jiang S. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. *J Immunol* 2006;176:6085–92.
- [53] Zeng LP, Ge XY, Peng C, Tai W, Jiang S, Du L, et al. Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. *Sci China Life Sci* 2017;60:1399–402.
- [54] Chen WH, Du L, Chag SM, Ma C, Tricoche N, Tao X, et al. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. *Hum Vaccines Immunother* 2014;10:648–58.
- [55] <http://www.smetimes.in/smetimes/news/global-business/2020/Jan/23/china-us-vaccine50374.html>.
- [56] Mehand MS, Al-Shorbaji F, Millett P, Murgue B. The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts. *Antivir Res* 2018;159:63–7.
- [57] Dyall J, Gross R, Kindrachuk J, Johnson RF, Olinger Jr GG, Hensley LE, et al. Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies. *Drugs* 2017;77:1935–66.
- [58] Jiang S, Lin K, Strick N, Neurath AR. HIV-1 inhibition by a peptide. *Nature* 1993;365:113.
- [59] Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. *Lancet* 2004;363:938–47.
- [60] Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. *Nat Commun* 2014;5:3067.
- [61] Xia S, Yan L. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. *Sci Adv* 2019;5:eaav4580.
- [62] Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. *Proc Natl Acad Sci U S A* 2004;101:9804–9.
- [63] Olsen CW, Corapi WV, Jacobson RH, Simkins RA, Saif LJ, Scott FW. Identification of antigenic sites mediating antibody-dependent enhancement of feline infectious peritonitis virus infectivity. *J Gen Virol* 1993;74(Pt 4):745–9.
- [64] Bakker AB, Marissen WE, Kramer RA, Rice AB, Weldon WC, Niezgodka M, et al. Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. *J Virol* 2005;79:9062–8.
- [65] Qiu H, Sun S, Xiao H, Feng J, Guo Y, Tai W, et al. Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection. *Antivir Res* 2016;132:141–8.
- [66] Pascal KE, Coleman CM, Mujica AO, Kamat V, Badithe A, Fairhurst J, et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. *Proc Natl Acad Sci U S A* 2015;112:8738–43.
- [67] Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. *Nat Med* 2004;10:871–5.
- [68] Corti D, Zhao J, Pedotti M, Simonelli L, Agnihothram S, Fett C, et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. *Proc Natl Acad Sci U S A* 2015;112:10473–8.
- [69] Chen Z, Bao L, Chen C, Zou T, Xue Y, Li F, et al. Human neutralizing monoclonal antibody inhibition of Middle East respiratory syndrome coronavirus replication in the common marmoset. *J Infect Dis* 2017;215:1807–15.
- [70] Xu J, Jia W, Wang P, Zhang S, Shi X, Wang X. Antibodies and vaccines against Middle East respiratory syndrome coronavirus. *Emerg Microb Infect* 2019;8:841–56.
- [71] Coughlin MM, Prabhakar BS. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. *Rev Med Virol* 2012;22:2–17.
- [72] Tang XC, Agnihothram SS, Jiao Y, Stanhope J, Graham RL, Peterson EC, et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. *Proc Natl Acad Sci U S A* 2014;111:E2018–26.
- [73] Sui J, Aird DR, Tamin A, Murakami A, Yan M, Yammanuru A, et al. Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. *PLoS Pathog* 2008;4:e1000197.
- [74] Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. *Lancet Infect Dis* 2014;14:1090–5.
- [75] Sheahan TP, Sims AC. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. *Sci Transl Med* 2017;9:eaal3653.
- [76] Gross AE, Bryson ML. Oral ribavirin for the treatment of noninfluenza respiratory viral infections: a systematic review. *Ann Pharmacother* 2015;49:1125–35.
- [77] Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. *Thorax* 2004;59:252–6.
- [78] Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. *J Infect* 2013;67:606–16.
- [79] Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. *JAMA* 2003;290:3222–8.
- [80] Belshaw R, Gardner A, Rambaut A, Pybus OG. Pacing a small cage: mutation and RNA viruses. *Trends Ecol Evol* 2008;23:188–93.